Virus
Human Metapneumovirus
HMPV
Citation & MTA:
If you want to use this virus material for publications, patent applications or in cooperation projects or if you want to transfer it to another person, check the MTA for terms of use.
The virus materil is only for non-commercial, nonclinical research, cannot be transfered to cooperation partners without written permission from the RKI. If the use of the virus materials results in a scientific publication, you need to provide RKI with a copy of the publication and you have to acknowledge RKI as the source of the materials, if it results in a patent or commercialisation of a product, you need tp inform the RKI before (60 days).
Strain/Type
Genus: Metapneumo-virus
HMPV A2C (20/2923)
HMPV B1 (20/3220)
Host tropism
Humans.
Chimpanzees.
Gorillas.
Route of Transmission
Transmission of HMPV is thought to occur through droplet infection.
Characteristics e.g. sensitizing or toxic effects, replication deficiant, not infectious, attenuated, inactivated (upload relevant documents)
Approved as biological safety measure if taken as recipient organism for genetic engineering?
According to § 5 section 1 GenTSV in conjunction with the criteria in Annex I GenTSV, human metapneumovirus (HMPV) is assigned to risk group 2 as a donor and recipient organism for genetic engineering work.
Genetically modified (GenTSV)
Risk group (BioStoffV)
2
Risk assessment
Risk accessment based on TRBA (Technical Rule for Biological Agents) 462 "Classification of viruses into risk groups": https://www.baua.de/DE/Angebote/Rechtstexte-und-Technische-Regeln/Regelwerk/TRBA/TRBA-462.html
Operation instructions (mandatory for RG2 and higher)
https://biostoffe.dguv.de/data?name=830756&lang=en
Occupational health care (according to ArbMedVV)
Optional health care:
In the case of tasks specifically involving contact and tasks involving incidental contact with biological agents classed as Risk Group 2 under the Biological Agents Ordinance (Biostoffverordnung, BioStoffV) or which involve a comparable risk, the employer must offer an optional health care. This does not apply when on account of the risk assessment and on account of the protective measures taken it can be assumed that there is no risk of infection.
An optional health care must also be offered if as a result of the exposure to biological agents
- a serious infectious illness is to be expected and post-exposure prophylatic measures are possible, or
- an infection has resulted.
Vaccination:
None available.
Storage location of aliquots in the Biolab (just click Bearbeiten in the right corner of the header to add or change information in the table and use the menue in the left header to e.g. add a row)
| source | virus strain | freezing date | virus amount per vial | stock was produced on | no. of aliquots | belongs to (full name) | rack/box in N2 tank or -80°C freezer and location (room, address) | comments |
|---|---|---|---|---|---|---|---|---|
